Ordena

Cercar

01/01/2023 A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
Muñoz A., Ay C., Grilz E., López S., Font C., Pachón V., Castellón V., Martínez-Marín V., Salgado M., Martínez E., Calzas J., Ortega L., Rupérez A., Salas E., Pabinger I., Soria J.M.. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(16)DOI:10.1200/JCO.22.00255. PMID:36730884. IF:42.100(Q1/1D).
01/01/2023 Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies
García-Calderón C.B., Sierro-Martínez B., García-Guerrero E., Sanoja-Flores L., Muñoz-García R., Ruiz-Maldonado V., Jimenez-Leon M.R., Delgado-Serrano J., Molinos-Quintana Á., Guijarro-Albaladejo B., Carrasco-Brocal I., Lucena J.-M., García-Lozano J.-R., Blázquez-Goñi C., Reguera-Ortega J.L., González-Escribano M.-F., Reinoso-Segura M., Briones J., Pérez-Simón J.A., Caballero-Velázquez T.. Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1152498. PMID:37122702. IF:5.700(Q1/3D).
01/01/2023 Evolution of quality indicators in acute stroke during the RACECAT Trial: Impact in the general population
Olive-Gadea, M, de la Ossa, NP, Jovin, T, Abilleira, S, Jimenez, X, Cardona, P, Chamorro, A, Flores, A, Silva, Y, Purroy, F, Marti-Fabregas, J, Rodriguez-Campello, A, Zaragoza, J, Krupinski, J, Canovas, D, Choco, MG, Mas, N, Palomeras, E, Cocho, D, Aragones, JM, Repullo, C, Sanjurjo, E, Carrion, D, Catena, E, Costa, X, Almendros, MC, Barcelo, M, Monedero, J, Rybyeva, M, Diaz, G, Ribo, M. Evolution of quality indicators in acute stroke during the RACECAT Trial: Impact in the general population. International Journal of Stroke. 2023; 18(2)DOI:10.1177/17474930221093523. PMID:35373657. IF:6.300(Q1/1D).
01/01/2023 First pass effect in posterior circulation occlusions: Analysis from the CICAT registry
Terceno, M, Silva, Y, Bashir, S, Chamorro, A, de la Ossa, NP, Hernandez-Perez, M, Castano, C, Camps-Renom, P, Wenger, D, Cardona, P, Molina, C, Rodriguez-Campello, A, Canovas, D, Purroy, F, Salvat-Plana, M, Serena, J. First pass effect in posterior circulation occlusions: Analysis from the CICAT registry. International Journal of Stroke. 2023; 18(2)DOI:10.1177/17474930221089772. PMID:35272563. IF:6.300(Q1/1D).
01/01/2023 Presence of Ceramidase Activity in Electronegative LDL
Puig N., Rives J., Estruch M., Aguilera-Simon A., Rotllan N., Camacho M., Colomé N., Canals F., Sánchez-Quesada J.L., Benitez S.. Presence of Ceramidase Activity in Electronegative LDL. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(1)DOI:10.3390/ijms24010165. PMID:36613609. IF:4.900(Q1/3D).
01/01/2023 Exposure to secondhand aerosol from electronic cigarettes at homes: A real-life study in four European countries
Amalia B., Fu M., Tigova O., Ballbè M., Paniello-Castillo B., Castellano Y., Vyzikidou V.K., O'Donnell R., Dobson R., Lugo A., Veronese C., Pérez-Ortuño R., Pascual J.A., Cortés N., Gil F., Olmedo P., Soriano J.B., Boffi R., Ruprecht A., Ancochea J., López M.J., Gallus S., Vardavas C., Semple S., Fernández E.. Exposure to secondhand aerosol from electronic cigarettes at homes: A real-life study in four European countries. The Science of the total environment. 2023; 854DOI:10.1016/j.scitotenv.2022.158668. PMID:36099951. IF:8.200(Q1/1D).
01/01/2023 Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes
Blanco R., Dómine M., González J.L., Loutfi S., Alfaro J., Saldaña J., Rubio J., Campos B., Hidalgo J., Barba A., Márquez D., Martin M., Olaverri A., Nadal E.. Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes. LUNG CANCER. 2023; 183DOI:10.1016/j.lungcan.2023.107318. PMID:37557022. IF:4.500(Q1/2D).
01/01/2023 Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden: A Nonrandomized Controlled Trial
Provencio M., Ortega A.L., Coves-Sarto J., Calvo V., Marsé-Fabregat R., Dómine M., Guirado M., Carcereny E., Fernández N., Álvarez R., Blanco R., León-Mateos L., Sánchez-Torres J.M., Sullivan I.G., Cobo M., Sánchez-Hernández A., Massuti B., Sierra-Rodero B., Mártinez-Toledo C., Serna-Blasco R., Romero A., Cruz-Bermúdez A.. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden: A Nonrandomized Controlled Trial. JAMA Oncology. 2023; 9(3)DOI:10.1001/jamaoncol.2022.5959. PMID:36520426. IF:22.300(Q1/1D).